Compare Hut 8 Corp (HUT) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hut 8 Corp vs Zimmer Biomet Holdings Inc — how do they compare? Hut 8 Corp trades at $84.27 (market cap $9.82B), while Zimmer Biomet Holdings Inc trades at $89.14 (market cap $16.95B). The key difference: Zimmer Biomet Holdings Inc is the larger of the two by market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while Hut 8 Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hut 8 Corp for 11 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| HUT | ZBH | |
|---|---|---|
Market Cap | $9.82B | $16.95B |
Volume | 10,272,678 | 2,505,240 |
Sector | Financials | Health |
52-Week High | $133.02 | $103.98 |
52-Week Low | $33.76 | $79.58 |
Typical Hold Time | 11 Days | 89 Days |
Enterprise Value | $17.25B | $24.02B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HUT trades at $79.59, down 10.87% today, amid bearish technical signals despite strong analyst support. The stock shows negative profitability with a -188.59% net income margin and has missed earnings expectations for three consecutive quarters. Recent positive developments include securing a $1.07 billion credit facility and growing institutional interest, positioning the company in the expanding AI infrastructure market.
While analyst consensus remains strongly bullish with a $162.69 price target, significant risks persist including ongoing losses, high valuation multiples, and competitive pressures in AI infrastructure. The stock's outlook hinges on successful execution of its business transformation and achieving profitability amid substantial capital investments.
Zimmer Biomet (ZBH) trades at $88.91, up 0.47% on the day, with a bearish technical signal but strong recent earnings beats. The company reported Q2 2026 EPS of $2.07, exceeding expectations, and maintains a solid gross profit margin of 69.87%. Revenue growth is steady, reaching $8.23B in 2025, though net income margin has moderated. Analyst consensus is a 'Buy' with a $103.11 price target, indicating potential upside from current levels.
The outlook for ZBH is cautiously optimistic, supported by earnings momentum and a diversified medical technology portfolio. Key risks include rising debt levels, with debt-to-asset ratio increasing to 32.57% in 2025, and competitive pressures in the healthcare sector. Institutional ownership trends show continued interest, but investors should monitor margin sustainability and capital expenditure efficiency.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hut 8 Corp
Hut 8 is one of North America's largest digital asset miners and infrastructure providers. It operates diversified data centers supporting Bitcoin mining and high-performance computing (HPC) for AI.
Read more on HUT →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
